Vaccines最新文献

{"title":"Nationwide Discrete Choice Experiment on Chinese Guardians' Preferences for HPV Vaccination for Mothers and Daughters.","authors":"Jun Zhao, Tianshuo Zhao, Sihui Zhang, Ninghua Huang, Juan Du, Yaqiong Liu, Qingbin Lu, Chao Wang, Fuqiang Cui","doi":"10.3390/vaccines12101186","DOIUrl":"https://doi.org/10.3390/vaccines12101186","url":null,"abstract":"<p><p><b>Background</b>: HPV vaccination is the key measure to prevent cervical cancer, but uptake in China lags behind global targets. Understanding Chinese guardians' preferences is key to improving vaccine acceptance and coverage. <b>Methods</b>: A nationwide online discrete choice experiment survey was conducted among 4933 Chinese guardians across seven provinces in 2022 to quantify preferences and willingness to pay. Attributes included effectiveness, safety, duration, valency, location, and out-of-pocket cost. <b>Results</b>: Out of the 4933 guardians who participated in the study, 4179 (84.72%) were mothers. More than 60% of the guardians belonged to the age group of 35-44 years. Additionally, over half of the respondents (53.15%) had daughters between the ages of 9 and 14 years. Respondents were open to accepting the HPV vaccine with 95% efficacy and exceptional safety. Guardians expressed a preference for longer protection duration (specifically 15 years (βa = 0.340, 95% CI: 0.31, 0.37)) and higher vaccine valency. As for willingness to pay, the respondents placed the highest value on vaccine efficacy, being willing to shell out more than USD 1100 for 95% protection as compared to 50%. Furthermore, very good safety commanded a premium of over USD 800 when compared to average safety. When it comes to willingness to uptake, a vaccine with 95% efficacy led to a more than 35% increase in acceptance as compared to one with 50% efficacy. Similarly, exceptional safety resulted in an increased willingness to uptake of over 25% when compared to average safety. <b>Conclusions</b>: The DCE highlighted effectiveness, safety, and durability as critical drivers of HPV vaccine acceptance, but substantial barriers persist regarding adolescent female coverage in China.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"12 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pertussis Outbreak During 2023 in Gipuzkoa, North Spain.","authors":"José María Marimón, Milagrosa Montes, Nahikari Vizuete, Lorea Alvarez Guerrico, Adrian Hugo Aginagalde, Alba Mir-Cros, Juan José González-López, Diego Vicente","doi":"10.3390/vaccines12101192","DOIUrl":"https://doi.org/10.3390/vaccines12101192","url":null,"abstract":"<p><strong>Background: </strong>Pertussis has re-emerged in many countries despite the wide use of vaccines for over 60 years. During 2023, we observed an increase in the incidence of pertussis in Gipuzkoa, north of Spain (with a population of 657,140 inhabitants), mainly affecting children between 11 and 15 years of age.</p><p><strong>Methods: </strong>This study included all confirmed cases diagnosed by PCR in nasopharyngeal swab samples. The genome of seven isolates collected in 2023 was sequenced.</p><p><strong>Results: </strong>Between 2018 and 2023, 884 cases of whooping cough were diagnosed. Pertussis incidence (in cases per 100,000 inhabitants) decreased from 36.7 in 2018 to no cases in 2021, increasing again to 56.8 in 2023. In 2023, the age group of 11-15 years old had the highest incidence rate of 409.3. Only 2 of the 56 children < 6 years old required hospitalization, and there were no deaths. The seven isolates collected in 2023 showed the same BPagST-4 (<i>ptxA1/ptxP3/prn2/fim2-1/fim3</i>-1 allelic combination), with all of them expressing the pertactin antigen.</p><p><strong>Conclusions: </strong>Immunity waning after the last dose of vaccination at 6 years old, together with the lack of circulation of <i>Bordetella pertussis</i> during the COVID-19 pandemic, were probably the main reasons for the high increase in the incidence of pertussis in Gipuzkoa in 2023.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"12 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Immunosuppressants and Vaccination on COVID-19 Outcomes in Autoimmune Patients and Solid Organ Transplant Recipients: A Nationwide Propensity Score-Matched Study.","authors":"Mindong Sung, Young-Sam Kim, Changjin Cho, Yongeun Son, Dong-Wook Kim, Su-Hwan Lee","doi":"10.3390/vaccines12101190","DOIUrl":"https://doi.org/10.3390/vaccines12101190","url":null,"abstract":"<p><strong>Purpose: </strong>This study investigates the impact of varying degrees of immunosuppression on the clinical outcomes of immunocompromised individuals, particularly those with autoimmune diseases or post-solid organ transplant statuses, in the context of COVID-19. By focusing on these highly vulnerable populations, the study underscores the significant health inequalities faced by immunocompromised patients, who experience disproportionately worse outcomes in comparison to the general population.</p><p><strong>Methods: </strong>A retrospective cohort analysis of the K-COV-N dataset was conducted, comparing the effects of immunosuppression in autoimmune and transplant groups with matched control groups. Propensity score matching was employed to minimize inequalities in baseline characteristics, ensuring a more equitable comparison between immunocompromised and non-immunocompromised individuals. Outcomes included COVID-19-related in-hospital mortality, 28-day mortality, ICU admissions, and the need for respiratory support among 323,890 adults in the Republic of Korea. Patients with cancer or other immunosuppressive conditions, such as HIV, were excluded. Subgroup analyses assessed the influence of specific immunosuppressive medications and vaccination extent.</p><p><strong>Results: </strong>Significantly elevated in-hospital mortality was found for patients with autoimmune diseases (adjusted Odds Ratio [aOR] 2.749) and transplant recipients (aOR 7.567), with similar patterns in other outcomes. High-dose steroid use and a greater number of immunosuppressant medications markedly increased the risk of poor outcomes. Vaccination emerged as a protective factor, with a single dose substantially improving outcomes for autoimmune patients and at least two doses necessary for transplant recipients.</p><p><strong>Conclusions: </strong>Immunocompromised patients, particularly those with autoimmune diseases and transplant recipients, are highly vulnerable to severe COVID-19 outcomes. High-dose steroid use and multiple immunosuppressants further increase risks. Vaccination significantly improves outcomes, with at least one dose benefiting autoimmune patients and two doses necessary for transplant recipients. Personalized vaccination schedules based on immunosuppression levels are essential to mitigate healthcare inequalities and improve outcomes, particularly in underserved populations, informing both clinical and public health strategies.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"12 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basic Properties and Development Status of Aluminum Adjuvants Used for Vaccines.","authors":"Jingyang Lan, Disong Feng, Xueshan He, Qianru Zhang, Rong Zhang","doi":"10.3390/vaccines12101187","DOIUrl":"https://doi.org/10.3390/vaccines12101187","url":null,"abstract":"<p><strong>Background: </strong>Aluminum adjuvants, renowned for their safety and efficacy, act as excellent adsorbents and vaccine immunogen enhancers, significantly contributing to innate, endogenous, and humoral immunity. An ideal adjuvant not only boosts the immune response but also ensures optimal protective immunity. Aluminum adjuvants are the most widely used vaccine adjuvants and have played a crucial role in both the prevention of existing diseases and the development of new vaccines. With the increasing emergence of new vaccines, traditional immune adjuvants are continually being researched and upgraded. The future of vaccine development lies in the exploration and integration of novel adjuvant technologies that surpass the capabilities of traditional aluminum adjuvants. One promising direction is the incorporation of nanoparticles, which offer precise delivery and controlled release of antigens, thereby enhancing the overall immune response.</p><p><strong>Conclusions: </strong>This review summarizes the types, mechanisms, manufacturers, patents, advantages, disadvantages, and future prospects of aluminum adjuvants. Although aluminum adjuvants have certain limitations, their contribution to enhancing vaccine immunity is significant and cannot be ignored. Future research should continue to explore their mechanisms of action and address potential adverse reactions to achieve improved vaccine efficacy.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"12 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Partial Protection of Goats against <i>Haemonchus contortus</i> Achieved with ADP-Ribosylation Factor 1 Encapsulated in PLGA Nanoparticles.","authors":"Muhammad Waqqas Hasan, Javaid Ali Gadahi, Muhammad Haseeb, Qiangqiang Wang, Muhammad Ehsan, Shakeel Ahmad Lakho, Ali Haider, Tahir Aleem, Mingmin Lu, Ruofeng Yan, Xiaokai Song, Xiangrui Li, Lixin Xu","doi":"10.3390/vaccines12101188","DOIUrl":"https://doi.org/10.3390/vaccines12101188","url":null,"abstract":"<p><strong>Background: </strong><i>Haemonchus contortus</i> (<i>H. contortus</i>), a nematode with global prevalence, poses a major threat to the gastrointestinal health of sheep and goats. In an effort to combat this parasite, a nanovaccine was created using a recombinant ADP-ribosylation factor 1 (ARF1) antigen encapsulated within poly lactic-co-glycolic acid (PLGA). This study aimed to assess the effectiveness of this nanovaccine in providing protection against <i>H. contortus</i> infection.</p><p><strong>Methods: </strong>Fifteen goats were randomly divided into three groups. The experimental group received two doses of the PLGA encapsulated rHcARF1 (rHcARF1-PLGA) nanovaccine on days 0 and 14. Fourteen days after the second immunization, both the experimental and positive control groups were challenged with 8000 infective larvae (L3) of <i>H. contortus</i>, while the negative control group remained unvaccinated and unchallenged. At the end of the experiment on the 63rd day, all animals were humanly euthanized.</p><p><strong>Results: </strong>The results showed that the experimental group had significantly higher levels of sera IgG, IgA, and IgE antibodies, as well as increased concentrations of cytokines, such as IL-4, IL-9, IL-17, and TGF-β, compared to the negative control group after immunization. Following the L3 challenge, the experimental group exhibited a 47.5% reduction in mean eggs per gram of feces (EPG) and a 55.7% reduction in worm burden as compared to the positive control group.</p><p><strong>Conclusions: </strong>These findings indicate that the nanovaccine expressing rHcARF1 offers significant protective efficacy against <i>H. contortus</i> infection in goats. The results also suggest the need for more precise optimization of the antigen dose or a reassessment of the vaccination regimen. Additionally, the small sample size limits the statistical rigor and the broader applicability of the findings.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"12 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Klebsiella pneumoniae</i> Lipopolysaccharide as a Vaccine Target and the Role of Antibodies in Protection from Disease.","authors":"Jernelle C Miller, Alan S Cross, Sharon M Tennant, Scott M Baliban","doi":"10.3390/vaccines12101177","DOIUrl":"https://doi.org/10.3390/vaccines12101177","url":null,"abstract":"<p><p><i>Klebsiella pneumoniae</i> is well recognized as a serious cause of infection in healthcare-associated settings and immunocompromised individuals; however, accumulating evidence from resource-limited nations documents an alarming rise in community-acquired <i>K</i>. <i>pneumoniae</i> infections, manifesting as bacteremia and pneumonia as well as neonatal sepsis. The emergence of hypervirulent and antibiotic-resistant <i>K</i>. <i>pneumoniae</i> strains threatens treatment options for clinicians. Effective vaccination strategies could represent a viable alternative that would both preempt the need for antibiotics to treat <i>K</i>. <i>pneumoniae</i> infections and reduce the burden of <i>K</i>. <i>pneumoniae</i> disease globally. There are currently no approved <i>K. pneumoniae</i> vaccines. We review the evidence for <i>K</i>. <i>pneumoniae</i> lipopolysaccharide (LPS) as a vaccine and immunotherapeutic target and discuss the role of antibodies specific for the core or O-antigen determinants within LPS in protection against <i>Klebsiella</i> spp. disease. We expand on the known role of the <i>Klebsiella</i> spp. capsule and O-antigen modifications in antibody surface accessibility to LPS as well as the in vitro and in vivo effector functions reported for LPS-specific antibodies. We summarize key hypotheses stemming from these studies, review the role of humoral immunity against <i>K</i>. <i>pneumoniae</i> O-antigen for protection, and identify areas requiring further research.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"12 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incremental Effectiveness of Emergency Vaccination Against a Varicella Outbreak at an Elementary School in Beijing, China, 2019: An Observational Cohort Study.","authors":"Zhiqiang Cao, Dan Zhao, Rujing Shi, Yanhong Zhao, Xiaojing Wen, Ying Ma, Xiaomei Li, Luodan Suo","doi":"10.3390/vaccines12101184","DOIUrl":"https://doi.org/10.3390/vaccines12101184","url":null,"abstract":"<p><p>(1) Background: The effect of varicella emergency vaccination (EV) has not been fully evaluated. (2) Methods: This was a cohort study. Participants were categorized into five groups based on their immune status: unvaccinated group, first dose as EV group, one dose no EV group, second dose as EV group, and two doses no EV group. A Cox proportional hazards model was employed to examine the association between the EV measures and the varicella incidence rate in this outbreak. (3) Results: Demographic characteristics, vaccination details, and disease onset information were 100% (918/918) collected. The crude attack rate was 44% (11/25), 8% (3/36), 11% (24/215), 3% (6/176), and 2% (8/466) among the unvaccinated group, first dose as EV group, one dose no EV group, second dose as EV group and two doses no EV group, respectively. Compared to the unvaccinated group and the one dose no EV group, the first dose varicella vaccine as EV and the second dose as EV demonstrated an incremental effectiveness of 90% (95% CI 65-97%) and 79% (95% CI 47-92%), respectively. (4) Conclusions: Both the first dose and the second dose as EV contributed to reducing the incidence rates of varicella and offered incremental vaccine effectiveness in an outbreak setting. Our study underscores the importance and benefits of initiating emergency varicella vaccination early to reduce the disease incidence rate in an elementary school setting where there was no complete coverage of the two doses of varicella vaccine and an outbreak occurred.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"12 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview of Recombinant Tick Vaccines and Perspectives on the Use of Plant-Made Vaccines to Control Ticks of Veterinary Importance.","authors":"Edgar Trujillo, Abel Ramos-Vega, Elizabeth Monreal-Escalante, Consuelo Almazán, Carlos Angulo","doi":"10.3390/vaccines12101178","DOIUrl":"https://doi.org/10.3390/vaccines12101178","url":null,"abstract":"<p><p>Ticks are obligate hematophagous ectoparasites that affect animals, and some of them transmit a wide range of pathogens including viruses, bacteria, and protozoa to both animals and humans. Several vaccines have shown immunogenicity and protective efficacy against ticks in animal models and definitive hosts. After several decades on anti-tick vaccine research, only a commercial vaccine based on a recombinant antigen is currently available. In this context, plants offer three decades of research and development on recombinant vaccine production to immunize hosts and as a delivery vehicle platform. Despite the experimental advances in plant-made vaccines to control several parasitosis and infectious diseases, no vaccine prototype has been developed against ticks. This review examines a panorama of ticks of veterinary importance, recombinant vaccine experimental developments, plant-made vaccine platforms, and perspectives on using this technology as well as the opportunities and limitations in the field of tick vaccine research.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"12 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142516679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What COVID-19 Vaccination Strategy Should Be Implemented and Which Vaccines Should Be Used in the Post-Pandemic Era?","authors":"Pedro Plans-Rubió","doi":"10.3390/vaccines12101180","DOIUrl":"https://doi.org/10.3390/vaccines12101180","url":null,"abstract":"<p><p>COVID-19 vaccines have reduced the negative health and economic impact of the COVID-19 pandemic by preventing severe disease, hospitalizations and deaths. In the new socio-economic normality, the COVID-19 vaccination strategy can be universal or high-risk and seasonal or not seasonal, and different vaccines can be used. The universal vaccination strategy can achieve greater health and herd immunity effects and is associated with greater costs than the high-risk vaccination strategy. In each country, the optimal COVID-19 vaccination strategy must be decided by considering the advantages and disadvantages and assessing the costs, health effects and cost-effectiveness of the universal and high-risk vaccination strategies. The universal vaccination strategy should be implemented when the objective of the vaccination program is to achieve the greatest health benefits from COVID-19 vaccination and when its incremental cost-effectiveness ratio is lower than EUR 30,000-50,000 per QALY or LYG. The use of adapted vaccines targeting currently circulating variants of SARS-CoV-2 is necessary to avoid the immune escape of emerging variants.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"12 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Vaccination Against <i>E. coli</i>, <i>C. perfringens</i> Type A/C on Piglet Productive and Clinical Parameters Under Field Conditions.","authors":"Arkadiusz Dors, Robert Panek, Wojciech Łużyński, Krzysztof Janeczko, Agata Augustyniak, Hanna Turlewicz-Podbielska, Ewelina Czyżewska-Dors, Małgorzata Pomorska-Mól","doi":"10.3390/vaccines12101185","DOIUrl":"https://doi.org/10.3390/vaccines12101185","url":null,"abstract":"<p><p><b>Background</b>: One of the main strategies to control neonatal porcine diarrhoea (NPD) is through vaccination of the sows. This study aimed to compare the efficacy of two commercial vaccination schemes under field conditions on a farm where a <i>C. perfringens</i> type A <i>cpb2</i>-positive strain was implicated in NPD. <b>Methods</b>: This study was performed in a farrow-to-wean herd with 5500 sows, already using an <i>E. coli</i> and <i>C. perfringens</i> vaccine but still suffering NPD. Where the presence of a <i>C. perfringens</i> type A <i>cpb2</i>-positive strain was confirmed, Enteroporc Coli AC^® (Ceva) was administrated to the sows in group A according to the manufacturer's instructions. Sows in group B were vaccinated using two other combined commercial vaccines. In each group, piglets from 10 litters were ear-tagged and individually weighed at birth and at 8 and 22 days of age. The incidence of diarrhoea, general piglet body condition, and antimicrobial treatment were recorded within 10 consecutive days after birth. <b>Results</b>: A total of 234 piglets (119 in group A and 115 in group B) were included. The mean weight gain of piglets from birth to 22 days of age was significantly higher in group A (4.99 kg) than in group B (4.66 kg) (<i>p</i> = 0.039). The rest of the recorded parameters such as the presence of diarrhoea, the piglet's body condition score, and the number of days with antimicrobial treatment did not differ significantly between groups. <b>Conclusions</b>: This study confirmed the efficiency of the Enteroporc Coli AC^® vaccine in reducing clinical symptoms of diarrhoea in piglets, which was comparable with the other vaccines used in the study. The positive effect on piglets' productive performance during the lactation phase was observed.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"12 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}